Cancer feature: cnaPANCAN415

ADAL ANKRD63 B2M BAHD1 BMF BUB1B C15orf52 C15orf54 C15orf56 C15orf57 C15orf62 CAPN3 CASC4 CASC5 CATSPER2 CCNDBP1 CDAN1 CHAC1 CHP1 CHST14 CKMT1A CKMT1B CTDSPL2 DISP2 DLL4 DNAJC17 EHD4 EIF2AK4 EIF3J ELL3 EPB42 EXD1 FRMD5 FSIP1 GANC GCHFR GPR176 HAUS2 HYPK INO80 ITPKA IVD JMJD7 JMJD7-PLA2G4B KNSTRN LCMT2 LRRC57 LTK MAP1A MAPKBP1 MFAP1 MGA NDUFAF1 NUSAP1 OIP5 PAK6 PATL2 PDIA3 PHGR1 PLA2G4B PLA2G4D PLA2G4E PLA2G4F PLCB2 PPIP5K1 PPP1R14D RAD51 RHOV RMDN3 RP11-133K1.2 RP11-296A16.1 RPAP1 RPUSD2 RTF1 SERF2 SERINC4 SNAP23 SPG11 SPINT1 SPTBN5 SRP14 STARD9 STRC TGM5 TGM7 THBS1 TMEM62 TMEM87A TP53BP1 TTBK2 TUBGCP4 TYRO3 UBR1 VPS18 VPS39 WDR76 ZFYVE19 ZNF106 ZSCAN29

Known Driver Genes: BUB1B

Copy number alternation: loss

GSK2110183B

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer